IPHYF
Innate Pharma S.A.
Price Chart
Latest Quote
$1.65
+0.00 (+0.00%)
Current Price
| Previous Close | $1.65 |
| Open | $2.18 |
| Day High | $2.25 |
| Day Low | $2.18 |
| Volume | 200 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 93.90M |
| Total Debt | $25.68M |
| Cash Equivalents | $39.03M |
| Revenue | $10.24M |
| Net Income | $-55.95M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $154.94M |
| EPS (TTM) | $-0.63 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $143.02M |
| Sales | $10.24M |
| Income | $-55.95M |
| Book/sh | $-0.27 |
| Cash/sh | $0.37 |
| Employees | 164 |
Financial Ratios
| Quick Ratio | 1.14 |
| Current Ratio | 1.27 |
Returns & Margins
| ROA | -38.85% |
| Operating Margin | -689.55% |
Ownership
| Insider Ownership | 20.77% |
| Institutional Ownership | 10.54% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 17.21 |
| P/B | -6.20 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.65 |
| SMA50 | $1.68 |
| SMA200 | $1.92 |
| RSI | nan |
| Shares Float | 70.54M |
| Volatility | 0.89 |
Performance History
| Week | +0.00% |
| Month | -26.67% |
| Quarter | +20.17% |
| 6 Months | -23.43% |
| YTD | -23.43% |
| Year | -4.90% |
| 3 Years | -50.60% |
| 5 Years | -53.52% |
| 10 Years | -84.07% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $1.65 | 0 |
| 2026-06-23 | $1.65 | 0 |
| 2026-06-22 | $1.65 | 0 |
| 2026-06-18 | $1.65 | 0 |
| 2026-06-17 | $1.65 | 0 |
| 2026-06-16 | $1.65 | 0 |
| 2026-06-15 | $1.65 | 0 |
| 2026-06-12 | $1.65 | 0 |
| 2026-06-11 | $1.65 | 0 |
| 2026-06-10 | $1.65 | 0 |
| 2026-06-09 | $1.65 | 0 |
| 2026-06-08 | $1.65 | 0 |
| 2026-06-05 | $1.65 | 0 |
| 2026-06-04 | $1.65 | 0 |
| 2026-06-03 | $1.65 | 0 |
| 2026-06-02 | $1.65 | 0 |
| 2026-06-01 | $1.65 | 0 |
| 2026-05-29 | $1.65 | 0 |
| 2026-05-28 | $1.65 | 0 |
| 2026-05-27 | $1.65 | 6,700 |
| 2026-05-26 | $2.25 | 0 |
About Innate Pharma S.A.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
đ° Latest News
How Innate Pharma (ENXTPA:IPH) Story Is Shifting Around 2026 Catalysts And âŦ8 Target
Simply Wall St. âĸ 2026-03-27T06:06:39Z
Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ...
GuruFocus.com âĸ 2026-03-26T19:00:56ZInnate Pharma Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-26T15:08:16Z
Innate Pharma Receives US FDA Clearance to Begin Phase 3 Trial of Potential Skin Cancer Therapy
MT Newswires âĸ 2025-11-10T09:45:58ZInnate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks âĸ 2025-11-06T14:55:02Z
How the Narrative Around Innate Pharma Is Shifting After Recent Strategic Decisions
Simply Wall St. âĸ 2025-09-20T12:21:56Z
Target initiated, Nike upgraded: Wall Street's top analyst calls
The Fly âĸ 2025-09-18T13:38:40Z
Innate Pharma SA (IPHA) (H1 2025) Earnings Call Highlights: Strategic Focus and Financial ...
GuruFocus.com âĸ 2025-09-18T07:00:54Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $12,621,000 | $51,901,000 | $49,580,000 | $12,110,000 |
| Operating Revenue | $12,565,000 | $51,890,000 | $50,197,000 | $12,110,000 |
| Expenses | ||||
| Interest Expense | $566,000 | $640,000 | $288,000 | $312,000 |
| Total Expenses | $64,197,000 | $64,570,000 | $66,005,000 | $59,937,000 |
| Other Income Expense | $232,000 | $2,562,000 | $-41,805,000 | $2,330,000 |
| Net Non Operating Interest Income Expense | $1,871,000 | $2,537,000 | $258,000 | $15,000 |
| Interest Expense Non Operating | $566,000 | $640,000 | $288,000 | $312,000 |
| Operating Expense | $64,197,000 | $64,570,000 | $66,005,000 | $59,937,000 |
| Other Operating Expenses | $284,000 | $-3,200,000 | $-131,000 | $-3,058,000 |
| General And Administrative Expense | $11,933,000 | $11,748,000 | $14,473,000 | $15,991,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-49,471,000 | $-7,570,000 | $-57,972,000 | $-45,478,000 |
| Net Interest Income | $1,871,000 | $2,537,000 | $258,000 | $15,000 |
| Interest Income | $2,437,000 | $3,177,000 | $546,000 | $327,000 |
| Normalized Income | $-49,703,000 | $-10,132,000 | $-16,167,000 | $-47,808,000 |
| Net Income From Continuing And Discontinued Operation | $-49,471,000 | $-7,570,000 | $-58,103,000 | $-52,809,000 |
| Total Operating Income As Reported | $-51,575,000 | $-12,669,000 | $-57,425,000 | $-47,825,000 |
| Net Income Common Stockholders | $-49,471,000 | $-7,570,000 | $-58,103,000 | $-52,809,000 |
| Net Income | $-49,471,000 | $-7,570,000 | $-58,103,000 | $-52,809,000 |
| Net Income Including Noncontrolling Interests | $-49,471,000 | $-7,570,000 | $-58,103,000 | $-52,809,000 |
| Net Income Discontinuous Operations | $0 | $0 | $-131,000 | $-7,331,000 |
| Net Income Continuous Operations | $-49,471,000 | $-7,570,000 | $-57,972,000 | $-45,478,000 |
| Pretax Income | $-49,471,000 | $-7,570,000 | $-57,972,000 | $-45,478,000 |
| Special Income Charges | $0 | $0 | $-41,000,000 | $0 |
| Interest Income Non Operating | $2,437,000 | $3,177,000 | $546,000 | $327,000 |
| Operating Income | $-51,576,000 | $-12,669,000 | $-16,425,000 | $-47,827,000 |
| Per Share | ||||
| Diluted EPS | $-0.61 | $-0.09 | $-0.73 | $-0.66 |
| Basic EPS | $-0.61 | $-0.09 | $-0.73 | $-0.66 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-47,143,000 | $-4,401,000 | $29,526,000 | $-42,900,000 |
| Total Unusual Items | $232,000 | $2,562,000 | $-41,805,000 | $2,330,000 |
| Total Unusual Items Excluding Goodwill | $232,000 | $2,562,000 | $-41,805,000 | $2,330,000 |
| Reconciled Depreciation | $1,994,000 | $5,091,000 | $45,405,000 | $4,596,000 |
| EBITDA (Bullshit earnings) | $-46,911,000 | $-1,839,000 | $-12,279,000 | $-40,570,000 |
| EBIT | $-48,905,000 | $-6,930,000 | $-57,684,000 | $-45,166,000 |
| Diluted Average Shares | $81,052,000 | $84,111,111 | $79,640,000 | $79,543,000 |
| Basic Average Shares | $81,052,000 | $84,111,111 | $79,640,000 | $79,543,000 |
| Diluted NI Availto Com Stockholders | $-49,471,000 | $-7,570,000 | $-58,103,000 | $-52,809,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Impairment Of Capital Assets | $0 | $0 | $41,000,000 | $0 |
| Gain On Sale Of Security | $232,000 | $2,562,000 | $-805,000 | $2,330,000 |
| Research And Development | $51,980,000 | $56,022,000 | $51,663,000 | $47,004,000 |
| Selling General And Administration | $11,933,000 | $11,748,000 | $14,473,000 | $15,991,000 |
| Other Gand A | $3,377,000 | $2,906,000 | $4,244,000 | $5,108,000 |
| Salaries And Wages | $8,556,000 | $8,842,000 | $10,229,000 | $10,883,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $8,834,000 | $51,485,000 | $52,598,000 | $63,250,000 |
| Total Assets | $111,059,000 | $175,187,000 | $199,295,000 | $267,496,000 |
| Total Non Current Assets | $25,317,000 | $27,175,000 | $59,465,000 | $129,241,000 |
| Other Non Current Assets | $575,000 | $87,000 | $152,000 | $150,000 |
| Non Current Accounts Receivable | $9,328,000 | $10,554,000 | $14,099,000 | $29,821,000 |
| Investmentin Financial Assets | $10,281,000 | $9,796,000 | $35,119,000 | $39,878,000 |
| Goodwill And Other Intangible Assets | $0 | $416,000 | $1,553,000 | $44,190,000 |
| Current Assets | $85,742,000 | $148,013,000 | $139,831,000 | $138,256,000 |
| Prepaid Assets | $3,329,000 | $9,067,000 | $7,324,000 | $4,946,000 |
| Receivables | $1,643,000 | $46,489,000 | $31,020,000 | $13,473,000 |
| Other Receivables | $89,000 | $104,000 | $61,000 | $814,000 |
| Taxes Receivable | $904,000 | $31,152,000 | $27,879,000 | $11,813,000 |
| Accounts Receivable | $650,000 | $15,233,000 | $3,080,000 | $846,000 |
| Cash Cash Equivalents And Short Term Investments | $80,770,000 | $92,456,000 | $101,485,000 | $119,836,000 |
| Cash And Cash Equivalents | $66,396,000 | $70,605,000 | $84,225,000 | $103,756,000 |
| Non Current Deferred Assets | - | $9,006,000 | $8,568,000 | $5,028,000 |
| Non Current Deferred Taxes Assets | - | $9,006,000 | $8,568,000 | $5,028,000 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | - | $9,796,000 | $35,119,000 | $39,878,000 |
| Other Intangible Assets | - | $416,000 | $1,553,000 | $44,190,000 |
| Other Current Assets | - | $1,000 | $2,000 | $1,000 |
| Debt | ||||
| Total Debt | $30,995,000 | $39,893,000 | $42,251,000 | $44,251,000 |
| Long Term Debt And Capital Lease Obligation | $22,286,000 | $30,957,000 | $40,149,000 | $13,503,000 |
| Long Term Debt | $22,182,000 | $30,607,000 | $38,929,000 | $11,491,000 |
| Current Debt And Capital Lease Obligation | $8,709,000 | $8,936,000 | $2,102,000 | $30,748,000 |
| Current Debt | $8,438,000 | $8,451,000 | $1,278,000 | $29,944,000 |
| Other Current Borrowings | $8,438,000 | $8,451,000 | $1,278,000 | $29,944,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $102,225,000 | $123,286,000 | $145,144,000 | $160,056,000 |
| Total Non Current Liabilities Net Minority Interest | $69,243,000 | $83,650,000 | $103,806,000 | $80,170,000 |
| Other Non Current Liabilities | $41,128,000 | $45,031,000 | $52,988,000 | $32,998,000 |
| Non Current Deferred Liabilities | $2,825,000 | $4,618,000 | $7,921,000 | $30,441,000 |
| Current Liabilities | $32,982,000 | $39,636,000 | $41,338,000 | $79,886,000 |
| Other Current Liabilities | $7,443,000 | $7,646,000 | $10,223,000 | $7,419,000 |
| Current Deferred Liabilities | $616,000 | $5,865,000 | $6,560,000 | $12,500,000 |
| Payables And Accrued Expenses | $16,007,000 | $17,018,000 | $20,911,000 | $28,572,000 |
| Payables | $16,007,000 | $17,018,000 | $20,911,000 | $28,572,000 |
| Other Payable | $1,122,000 | $1,436,000 | $1,277,000 | $6,380,000 |
| Total Tax Payable | $6,962,000 | $7,021,000 | $5,978,000 | $7,463,000 |
| Accounts Payable | $7,923,000 | $8,561,000 | $13,656,000 | $14,729,000 |
| Non Current Deferred Taxes Liabilities | - | $9,006,000 | $8,568,000 | $5,028,000 |
| Equity | ||||
| Common Stock Equity | $8,834,000 | $51,901,000 | $54,151,000 | $107,440,000 |
| Total Equity Gross Minority Interest | $8,834,000 | $51,901,000 | $54,151,000 | $107,440,000 |
| Stockholders Equity | $8,834,000 | $51,901,000 | $54,151,000 | $107,440,000 |
| Gains Losses Not Affecting Retained Earnings | $27,000 | $495,000 | $819,000 | $456,000 |
| Other Equity Adjustments | $27,000 | $495,000 | $819,000 | $456,000 |
| Retained Earnings | $-386,364,000 | $-336,893,000 | $-330,316,000 | $-272,213,000 |
| Other Equity Interest | - | - | - | $-1,000 |
| Other | ||||
| Treasury Shares Number | $18,575 | $18,575 | - | $18,575 |
| Ordinary Shares Number | $83,811,761 | $80,841,988 | $79,542,627 | $79,542,627 |
| Share Issued | $83,830,336 | $80,860,563 | $79,542,627 | $79,561,202 |
| Tangible Book Value | $8,834,000 | $51,485,000 | $52,598,000 | $63,250,000 |
| Invested Capital | $39,454,000 | $90,959,000 | $94,358,000 | $148,875,000 |
| Working Capital | $52,760,000 | $108,377,000 | $98,493,000 | $58,370,000 |
| Capital Lease Obligations | $375,000 | $835,000 | $2,044,000 | $2,816,000 |
| Total Capitalization | $31,016,000 | $82,508,000 | $93,080,000 | $118,931,000 |
| Additional Paid In Capital | $390,979,000 | $384,255,000 | $379,637,000 | $375,220,000 |
| Capital Stock | $4,192,000 | $4,044,000 | $4,011,000 | $3,978,000 |
| Common Stock | $4,192,000 | $4,044,000 | $4,011,000 | $3,978,000 |
| Employee Benefits | $2,730,000 | $2,441,000 | $2,550,000 | $2,975,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $2,730,000 | $2,441,000 | $2,550,000 | $2,975,000 |
| Non Current Deferred Revenue | $2,825,000 | $4,618,000 | $7,921,000 | $25,413,000 |
| Long Term Capital Lease Obligation | $104,000 | $350,000 | $1,220,000 | $2,012,000 |
| Long Term Provisions | $274,000 | $603,000 | $198,000 | $253,000 |
| Current Deferred Revenue | $616,000 | $5,865,000 | $6,560,000 | $12,500,000 |
| Current Capital Lease Obligation | $271,000 | $485,000 | $824,000 | $804,000 |
| Current Provisions | $207,000 | $171,000 | $1,542,000 | $647,000 |
| Investments And Advances | $10,281,000 | $9,796,000 | $35,119,000 | $39,878,000 |
| Net PPE | $5,133,000 | $6,322,000 | $8,542,000 | $10,174,000 |
| Gross PPE | $5,133,000 | $6,322,000 | $8,542,000 | $10,174,000 |
| Leases | $1,269,000 | $1,675,000 | - | - |
| Construction In Progress | $0 | $0 | $0 | $6,000 |
| Other Properties | $2,861,000 | $3,377,000 | $4,300,000 | $5,187,000 |
| Land And Improvements | $1,016,000 | $1,283,000 | $4,242,000 | - |
| Properties | $0 | $0 | $0 | $4,981,000 |
| Other Short Term Investments | $14,374,000 | $21,851,000 | $17,260,000 | $16,080,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-7,287,000 | $-34,910,000 | $-20,277,000 | $-59,787,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-6,896,000 | $-32,559,000 | $-19,155,000 | $-58,457,000 |
| Cash Flow From Continuing Operating Activities | $-6,896,000 | $-32,559,000 | $-19,155,000 | $-58,458,000 |
| Operating Gains Losses | $-541,000 | $308,000 | $-547,000 | $-1,066,000 |
| Investing Activities | ||||
| Capital Expenditure | $-391,000 | $-2,351,000 | $-1,122,000 | $-1,330,000 |
| Investing Cash Flow | $9,200,000 | $20,630,000 | $1,877,000 | $-917,000 |
| Cash Flow From Continuing Investing Activities | $9,199,000 | $20,630,000 | $1,877,000 | $-917,000 |
| Net Other Investing Changes | $1,000 | $63,000 | $-1,000 | $39,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-6,008,000 | $-1,966,000 | $-1,828,000 | $26,819,000 |
| Cash Flow From Continuing Financing Activities | $-6,008,000 | $-1,966,000 | $-1,828,000 | $26,818,000 |
| Cash Dividends Paid | - | $0 | $0 | $0 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Other Financing Charges | - | - | - | $1,000 |
| Net Common Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-8,936,000 | $-2,361,000 | $-2,026,000 | $-2,069,000 |
| End Cash Position | $66,396,000 | $70,605,000 | $84,225,000 | $103,756,000 |
| Beginning Cash Position | $70,605,000 | $84,225,000 | $103,756,000 | $136,792,000 |
| Effect Of Exchange Rate Changes | $-505,000 | $274,000 | $-428,000 | $-483,000 |
| Changes In Cash | $-3,704,000 | $-13,894,000 | $-19,103,000 | $-32,553,000 |
| Proceeds From Stock Option Exercised | $2,928,000 | $395,000 | $198,000 | $499,000 |
| Net Issuance Payments Of Debt | $-8,936,000 | $-2,361,000 | $-2,026,000 | $26,631,000 |
| Net Long Term Debt Issuance | $-8,936,000 | $-2,361,000 | $-2,026,000 | $26,631,000 |
| Long Term Debt Payments | $-8,936,000 | $-2,361,000 | $-2,026,000 | $-2,069,000 |
| Net Investment Purchase And Sale | $9,590,000 | $22,768,000 | $3,000,000 | $0 |
| Sale Of Investment | $9,590,000 | $22,768,000 | $3,000,000 | $0 |
| Net Intangibles Purchase And Sale | $0 | $-2,000,000 | $-587,000 | $-401,000 |
| Purchase Of Intangibles | $0 | $-2,000,000 | $-587,000 | $-401,000 |
| Net PPE Purchase And Sale | $-391,000 | $-201,000 | $-535,000 | $-922,000 |
| Sale Of PPE | $0 | $150,000 | $0 | $7,000 |
| Purchase Of PPE | $-391,000 | $-351,000 | $-535,000 | $-929,000 |
| Change In Working Capital | $39,162,000 | $-32,092,000 | $-12,503,000 | $-9,885,000 |
| Other Non Cash Items | $-356,000 | $6,000 | $133,000 | $-927,000 |
| Stock Based Compensation | $3,944,000 | $4,256,000 | $4,249,000 | $2,617,000 |
| Unrealized Gain Loss On Investment Securities | $-1,335,000 | $-1,592,000 | $1,372,000 | $-987,000 |
| Provisionand Write Offof Assets | $-293,000 | $-966,000 | $839,000 | $4,000 |
| Depreciation Amortization Depletion | $1,994,000 | $5,091,000 | $45,405,000 | $4,596,000 |
| Depreciation And Amortization | $1,994,000 | $5,091,000 | $45,405,000 | $4,596,000 |
| Pension And Employee Benefit Expense | $324,000 | $285,000 | $365,000 | $437,000 |
| Net Foreign Currency Exchange Gain Loss | $-885,000 | $544,000 | $-912,000 | $-1,136,000 |
| Gain Loss On Sale Of PPE | $20,000 | $470,000 | $0 | $0 |
| Net Income From Continuing Operations | $-49,471,000 | $-7,570,000 | $-58,103,000 | $-52,809,000 |
| Issuance Of Debt | - | $0 | $0 | $28,700,000 |
| Interest Paid Cff | - | $0 | $0 | $-312,000 |
| Long Term Debt Issuance | - | $0 | $0 | $28,700,000 |
| Interest Received Cfi | - | $0 | $0 | $367,000 |
| Purchase Of Investment | - | $0 | $0 | $0 |
| Change In Other Working Capital | - | - | $-23,432,000 | $-6,060,000 |
| Change In Other Current Liabilities | - | - | $22,796,000 | $-6,271,000 |
| Change In Payables And Accrued Expense | - | - | $-7,662,000 | $-946,000 |
| Change In Payable | - | - | $-7,662,000 | $-946,000 |
| Change In Account Payable | - | - | $-7,662,000 | $-946,000 |
| Change In Receivables | - | - | $-4,204,000 | $3,394,000 |
| Changes In Account Receivables | - | - | $-4,204,000 | $3,394,000 |
| Gain Loss On Investment Securities | - | - | $-912,000 | $-1,136,000 |
Fetched: 2026-02-02